UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS COMPLAINT AND DEMAND FOR JURY TRIAL Case No. 3:17-cv-130 Division No. COMPLAINT PLAINTIFFS, IRMA COLEMAN, (alternatively referred to as “Plaintiff) and JAMES B. COLEMAN, (hereinafter “Plaintiff-Spouse”), domiciled in RAMSEY (FAYETTE COUNTY) within the State of ILLINOIS, by and through the undersigned attorneys, hereby bring this cause of action against Defendants AstraZeneca Pharmaceuticals LP (“AstraZeneca Pharmaceuticals”), AstraZeneca LP, Procter & Gamble Manufacturing Company (“Procter & Gamble Manufacturing”) and The Procter & Gamble Company (collectively “Defendants”) and as for their Complaint alleges, upon information and belief and based on the investigation to date of counsel, as follows: IRMA COLEMAN and JAMES B COLEMAN, h/w Plaintiffs, v. ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA LP; PROCTER & GAMBLE MANUFACTURING COMPANY; and THE PROCTER & GAMBLE COMPANY ABC CORPORATIONS, 1-10, the fictitious names for unknown companies and/or other business entities; JOHN DOES, 1-10, the fictitious names for unknown companies and/or other business entities; and JANE DOES, 1-10, the fictitious names for unknown companies and/or other business entities and/or other business entities Defendants. Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 1 of 31 Page ID #1
36
Embed
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF … · esophagitis, maintenance of healing erosive esophagitis, and treatment of GERD. 39. AstraZeneca Pharmaceutical LP is the holder
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
UNITED STATES DISTRICT COURTSOUTHERN DISTRICT OF ILLINOIS
COMPLAINT AND DEMAND FOR JURY TRIAL
Case No. 3:17-cv-130
Division No.
COMPLAINT
PLAINTIFFS, IRMA COLEMAN, (alternatively referred to as “Plaintiff) and
JAMES B. COLEMAN, (hereinafter “Plaintiff-Spouse”), domiciled in RAMSEY
(FAYETTE COUNTY) within the State of ILLINOIS, by and through the undersigned
attorneys, hereby bring this cause of action against Defendants AstraZeneca Pharmaceuticals LP
(“AstraZeneca Pharmaceuticals”), AstraZeneca LP, Procter & Gamble Manufacturing Company
(“Procter & Gamble Manufacturing”) and The Procter & Gamble Company (collectively
“Defendants”) and as for their Complaint alleges, upon information and belief and based on the
investigation to date of counsel, as follows:
IRMA COLEMAN and JAMES B COLEMAN, h/w
Plaintiffs, v.
ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA LP; PROCTER & GAMBLE MANUFACTURING COMPANY; and THE PROCTER & GAMBLE COMPANY ABC CORPORATIONS, 1-10, the fictitious names for unknown companies and/or other business entities; JOHN DOES, 1-10, the fictitious names for unknown companies and/or other business entities; and JANE DOES, 1-10, the fictitious names for unknown companies and/or other business entities and/or other business entities
Defendants.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 1 of 31 Page ID #1
2
NATURE OF ACTION
1. This is a personal injury action against Defendants, AstraZeneca Pharmaceuticals LP
AstraZeneca LP, Procter & Gamble Manufacturing Company and The Procter & Gamble
Company and their affiliates, subsidiaries, alter-egos, and/or joint-venturers who were
responsible for designing, researching, developing, testing, manufacturing, packaging, labeling,
55. Defendants concealed and continue to conceal their knowledge of PPIs’ unreasonably
dangerous risks from Plaintiff, her physicians, other consumers, and the medical community.
Specifically, Defendants failed and continue to fail to adequately inform and warn consumers
and the prescribing medical community about the magnified risk of kidney injuries related to the
use of PPIs including Nexium, Prilosec and Prilosec OTC.
56. As a result of Defendants actions and inactions, Plaintiff was injured due to her
ingestion of Nexium, Prilosec and Prilosec OTC, which caused and will continue to cause
Plaintiff’s injuries and damages. Plaintiff accordingly seeks damages associated with these
injuries and sequelae.
FACTUAL ALLEGATIONS
57. Over 60 million Americans experience heartburn, a major symptom of GERD, at
least once a month and some studies have suggested more than 15 million Americans experience
heartburn on a daily basis.
58. About 21 million Americans used one or more prescription PPIs in 2009 accounting
for nearly 20% of the drugs’ global sales and earning an estimated $11 billion annually.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 10 of 31 Page ID #10
11
59. Upon information and belief, from 2003 to the present, PPIs have been one of the top
ten best-selling and most dispensed forms of prescription medication in the United States each
year.
60. PPIs are one of the most commercially successful groups of medication in the United
States. Upon information and belief, between the period of 2008 and 2013, prescription PPIs had
a sale of over $50 billion with approximately 240 million units dispensed.
61. Defendants, directly or through their agents, apparent agents, servants, or employees
designed, manufactured, marketed, advertised, distributed, promoted, and sold PPIs, including
Nexium, Prilosec, and Prilosec OTC.
62. In October of 1992, three years after the FDA’s initial PPI approval, researchers from
the University of Arizona Health Sciences Center led by Stephen Ruffenach published the first
article associating PPI usage with kidney injuries in The American Journal of Medicine,
followed by years of reports from national adverse drug registries describing this association.
63. In 2006, researchers at the Yale School of Medicine conducted a case series
published in the International Society of Nephrology’s Kidney International finding that PPI use,
by way of AIN, left most patients “with some level of chronic kidney disease.”
64. In 2007, F. Sierra et al. published an article in the Journal of Alimentary
Pharmacology and Therapeutics, titled, “Systematic review: proton pump inhibitor-associated
acute interstitial nephritis.” The researchers concluded that long term use of proton pump
inhibitors is associated with interstitial nephritis.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 11 of 31 Page ID #11
12
65. In February 2007, Harmark et al. published an article in the British Journal of
Clinical Pharmacology titled “Proton pump inhibitor-induced acute interstitial nephritis.” The
article states:
Our reports show that AIN can be induced by various PPIs. This assumption is supported by data from the World Health Organization Collaborating Centre for International Drug Monitoring in Uppsala, Sweden, where PPI-induced AIN is disproportionately present in the database. The reporting odds ratios are presented in Table 2. This databank contains more than 3.7 million spontaneous reports of adverse drug reactions from more than 80 countries worldwide. About 150 of these concern PPI-induced AIN, showing that this is a relatively rare condition.
66. On August 23, 2011, Public Citizen, a consumer advocacy group, filed a petition with
the FDA to add black box warnings and other safety information concerning several risks
associated with PPIs, including AIN.
67. According to the petition, at the time of its filing there was “no detailed risk
information on any PPI for this adverse effect.”
68. On October 31, 2014, more than three years after Public Citizen’s petition, the FDA
responded by requiring consistent labeling regarding risk of AIN on all prescription PPIs.
69. The FDA noted “that the prescription PPI labeling should be consistent with regard to
this risk” and that “there is reasonable evidence of a causal association.”
70. In December of 2014, the labels of prescription PPIs were updated to read:
Acute interstitial nephritis has been observed in patients taking PPIs including [Brand]. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue [PPI] if acute interstitial nephritis develops.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 12 of 31 Page ID #12
13
71. The FDA did not require the consistent labeling regarding risk of AIN on over-the-
counter PPIs.
72. In January of 2016, a study published in the Journal of the American Medical
Association found that PPI use was independently associated with a 20-50% higher risk of CKD.
73. In February of 2016, a study published in the Journal of the American Society of
Nephrology found that “exposure to PPI is associated with increased risk of development of
CKD, progression of kidney disease, and risk of ESRD.”
74. To date, over-the-counter PPIs lack detailed risk information for AIN.
75. To date, prescription and over-the-counter PPIs lack detailed risk information for
CKD including those manufactured by Defendants, specifically Nexium, Prilosec, and Prilosec
OTC that were taken by Plaintiff.
76. Parietal cells in the stomach lining secrete gastric juices containing hydrochloric acid
to catalyze the digestion of proteins.
77. Excess acid secretion results in the formation of most ulcers in the gastroesophageal
system and symptoms of heartburn and acid reflux.
78. PPIs irreversibly block the acidic hydrogen/potassium ATPase enzyme system
(H+/K+ ATPase) of the gastric parietal cells, thereby halting the production of most hydrochloric
acid.
79. In spite of their commercial success and global popularity, up to 70% of PPIs may be
used inappropriately for indications or durations that were never tested or approved.
80. As a result of the defective nature of PPIs, even if used as directed by a physician or
healthcare professional, persons who ingested PPIs have been exposed to significant risks
stemming from unindicated and/or long-term usage.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 13 of 31 Page ID #13
14
81. From these findings, PPIs and/or their metabolites—substances formed via
metabolism—have been found to deposit within the spaces between the tubules of the kidney and
act in such a way to mediate acute interstitial nephritis (“AIN”), a sudden kidney inflammation
that can result in mild to severe problems.
82. PPI-induced AIN is difficult to diagnose with less than half of patients reporting a
fever and, instead, most commonly complaining of non-specific symptoms such as fatigue,
nausea, and weakness.
83. AIN’s slow presentation can cause significant damage over time without those
affected exhibiting acute symptoms.
84. PPI-induced AIN exclusively affects the kidney’s interstitial tissue, rather than the
kidney’s glomeruli, as seen is non-PPI induced kidney injury.
85. Unlike many forms of AIN, PPI-induced AIN results in an excess of white blood cells
in the urine, indicating an immunological response.
86. In April 2016, a study published in the Journal of Nephrology suggested that the
development of and failure to treat AIN could lead to chronic kidney disease and end-stage renal
disease, which requires dialysis or kidney transplant to manage.
87. Analyses of the study were adjusted for age, sex, race, baseline eGFR, cigarette
smoking, BMI, systolic blood pressure, diabetes, a history of cardiovascular disease,
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 26 of 31 Page ID #26
27
letters, and regulatory submissions that the products were safe, and
withheld and concealed information about the substantial risks of serious
injury associated with long term use of PPIs;
b. Defendants represented that PPIs were safe to use every day;
143. In reliance upon Defendants’ implied warranty, Plaintiff, Irma Coleman used said
PPIs and in the foreseeable manner promoted, instructed, and marketed by Defendants.
144. Defendants breached their implied warranty to, Plaintiff, Irma Coleman in that PPIs
are not of merchantable quality, safe and fit for their intended use, or adequately tested.
145. In using PPIs, Plaintiff and her physicians relied on the skill, judgment,
representations, and foregoing express warranties of Defendants. These warranties and
representations proved to be false because the product was not safe and was unfit for the uses for
which it was intended.
146. As a direct and proximate result of Defendants’ breach of warranty as described
herein, Plaintiff, Irma Coleman suffered the injuries and damages as set forth above.
WHEREFORE, Plaintiff respectfully requests that this Court enter judgment in Plaintiff's
favor for compensatory and punitive damages, together with interest, costs herein incurred,
attorneys' fees, and all such other and further relief as this Court deems just and proper. Plaintiff
also demands that the issues herein contained be tried by a jury.
COUNT V FRAUDULENT MISREPRESENTATION AND OMISSION
147. Plaintiff incorporates by reference, as if fully set forth herein, each and every
allegation set forth in the preceding paragraphs and further allege as follows.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 27 of 31 Page ID #27
28
148. Defendant, having undertaken design, formulation, testing, manufacture, marketing,
sale, and distribution of PPIs owed a duty to provide accurate and complete information
regarding said drug.
149. Defendants fraudulently misrepresented that the daily use of their PPI was safe and
effective.
150. Defendant had a duty to provide consumers with true and accurate information
regarding the PPIs it manufactured, marketed, distributed and sold.
151. Defendants made representations and failed to disclose material facts with the intent
to induce consumers, including Plaintiff, Irma Coleman and the medical community to act in
reliance by purchasing and using the proton pump inhibitor sold by Defendants.
152. Plaintiff, Irma Coleman and the medical community justifiably relied on
Defendants’ representations and omissions by purchasing and taking proton pump inhibitors.
153. As a direct and proximate result of Defendants’ representations and omissions as
described herein, Plaintiff, Irma Coleman suffered the injuries and damages as set forth above.
WHEREFORE, Plaintiff respectfully requests that this Court enter judgment in Plaintiff's
favor for compensatory and punitive damages, together with interest, costs herein incurred,
attorneys' fees, and all such other and further relief as this Court deems just and proper. Plaintiff
also demands that the issues herein contained be tried by a jury.
COUNT VI LOSS OF CONSORTIUM
154. Plaintiffs incorporate by reference each proceeding and succeeding paragraph as
though set forth fully at length herein.
155. Plaintiff- Spouse is the husband of Irma Coleman, and was her lawful husband on all
material and relevant dates.
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 28 of 31 Page ID #28
29
156. As a direct and proximate result of the negligence and other acts omissions of
Defendants, described within the previous Counts of this Complaint, Plaintiff -Spouse has
suffered a loss of consortium, society, affections and services of his wife, Irma Coleman, as well
as other economic damages.
WHEREFORE, Plaintiffs respectfully requests that this Court enter judgment in
Plaintiffs’ favor for compensatory and punitive damages, together with interest, costs herein
incurred, attorneys' fees, and all such other and further relief as this Court deems just and proper.
Plaintiffs also demands that the issues herein contained be tried by a jury.
PUNITIVE DAMAGES ALLEGATIONS
157. The acts, conduct, and omissions of Defendants, as alleged throughout this
Complaint were willful and malicious. Defendants committed these acts with a conscious
disregard for the rights, health and safety of Irma Coleman and other PPI users and for the
primary purpose of increasing Defendants’ profits from the sale and distribution of PPIs.
Defendants’ outrageous and unconscionable conduct warrants an award of exemplary and
punitive damages against Defendants in an amount appropriate to punish and make an example
of Defendants.
158. Prior to the manufacturing, sale, and distribution of Nexium, Prilosec, and Prilosec
OTC, Defendants knew that said medication was in a defective condition as previously described
herein and knew that those who were prescribed the medication would experience and did
experience severe physical, mental, and emotional injuries. Further, Defendants, through their
officers, directors, managers, and agents, knew that the medication presented a substantial and
unreasonable risk of harm to the public, including Irma Coleman and as such, Defendants
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 29 of 31 Page ID #29
30
unreasonably subjected consumers of said drugs to risk of injury or kidney failure from using
PPIs.
159. Despite its knowledge, Defendants, acting through its officers, directors and
managing agents for the purpose of enhancing Defendants’ profits, knowingly and deliberately
failed to remedy the known defects in Nexium, Prilosec, and Prilosec OTC, and failed to warn
the public, including Plaintiff, of the extreme risk of injury occasioned by said defects inherent in
Nexium, Prilosec, and Prilosec OTC. Defendants and their agents, officers, and directors
intentionally proceeded with the manufacturing, sale, and distribution and marketing of Nexium,
Prilosec, and Prilosec OTC knowing these actions would expose persons to serious danger in
order to advance Defendants’ pecuniary interest and monetary profits.
160. Defendants’ conduct was despicable and so contemptible that it would be looked
down upon and despised by ordinary decent people, and was carried on by Defendants with
willful and conscious disregard for the safety of Irma Coleman, entitling Plaintiff to exemplary
damages.
PRAYER FOR RELIEF
WHEREFORE, for the foregoing reasons, Plaintiffs prays the Court for judgment against
Defendants in an amount to be determined at trial, as appropriate for:
a. compensatory, restitution and general damages in an amount that is fair and
reasonable and just;
b. punitive damages, against Defendants as appropriate, in the amount set forth above;
c. reasonable and/or statutory attorneys’ fees under state laws;
d. costs of suit;
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 30 of 31 Page ID #30
31
e. prejudgment and post judgment interest thereon at 8% or other appropriate rate as
provided for by statute; and
f. such other and further relief as the Court deems just, appropriate and equitable.
DEMAND FOR JURY TRIAL
Plaintiffs hereby demand a trial by jury on all claims so triable.
Date: February 8, 2017 Respectfully submitted,
/s/ Roger C. Denton Roger C. Denton, Esq. (#6182610) Dana J. Hantack, Esq. (#6322567) SCHLICHTER, BOGARD & DENTON, LLP 100 South 4th Street Saint Louis, MO 63102 314-621-6115 314-621-7151 (fax) [email protected]@uselaws.com
/s/ Paul J. Pennock Paul J. Pennock (PP3315) WEITZ & LUXENBERG, P.C. 700 BroadwayNew York, New York 10003 Phone: (212) 558-5500 Fax: (212) 363-2721 [email protected]
ATTORNEYS FOR PLAINTIFF
Case 3:17-cv-00130 Document 1 Filed 02/08/17 Page 31 of 31 Page ID #31
Foreign Country
CON TRACT TORTS I FORFEITURE/PEN AL rv I BANiatuvrey OTHER SIAIUTES
Case 3:17-cv-00130 Document 1-1 Filed 02/08/17 Page 1 of 1 Page ID #32
JS 44 (Rev. 07/16) CIVIL COVER SHEETThe JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as
provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the
purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ONNEXT PAGE OF THIS FORM)
I. (a) PLAINTIFFS DEFENDANTSIRMA COLEMAN and JAMES B COLEMAN ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA LP;
PROCTER & GAMBLE MANUFACTURING COMPANY; PROCTER &GAMBLE COMPANY
(b) County of Residence of First Listed Plaintiff FAYETTE COUNTY County ofResidence ofFirst Listed Defendant NEW CASTLE, DE
(EXCEPT IN US. PLAINTIFF CASES) (IN U.S PLAINTIFF CASES ONLY)NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF
II. BASIS OF JURISDICTION (Place an "X" in One Box Only) III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff(For Diversiry Cases Only) and One Box for Defendant)
ID 1 U.S. Government 0 3 Federal Question PTF DEF PTF DEF
Plaintiff (U.S. Government Not a Party) Citizen of This State GX 1 0 1 Incorporated or Principal Place 0 4 0 4of Business In This State
CI 2 U.S. Govemment g 4 Diversity Citizen of Another State CI 2 0 2 Incorporated and Principal Place 0 5 5
Defendant (Indicate Citizenship ofParties in Dem /IV of Business In Another State
Citizen or Subject of a 0 3 CI 3 Foreign Nation 0 6 0 6
IV. NATURE OF SUIT (Place an "X" in One Box Only)
O 110 Insurance PERSONAL INJURY PERSONAL INJURY 0 625 Drug Related Seizure 0 422 Appeal 28 USC 158 CI 375 False Claims Act
O 120 Marine 0 310 Airplane 0 365 Personal Injury of Property 21 USC 881 0 423 Withdrawal 0 376 QUi Tam(31 USC
CI 130 Miller Act CI 315 Airplane Product Product Liability 0 690 Other 28 USC 157 3729(a))0 140 Negotiable Instrument Liability tg 367 Health Care/ 0 400 State ReapportionmentCI 150 Recovery of Overpayment 0 320 Assault, Libel & Pharmaceutical gRopERTy WGLITS 0 410 Antitrust
& Enforcement ofJudgment Slander Personal Injury 0 820 Copyrights CI 430 Banks and Banking
CI 151 Medicare Act CI 330 Federal Employers' Product Liability 0 830 Patent 0 450 Commerce
O 152 Recovery of Defaulted Liability 0 368 Asbestos Personal 0 840 Trademark 0 460 DeportationStudent Loans 0 340 Marine Injury Product 0 470 Racketeer Influenced and
(Excludes Veterans) CI 345 Marine Product Liability LABOR SOCIAL SECURI TT Corrupt OrganizationsCI 153 Recovery of Overpayment Liability PERSONAL PROPERTY 0 710 Fair Labor Standards 0 861 HIA (139511) CI 480 Consumer Credit
ofVeteran's Benefits 0 350 Motor Vehicle 0 370 Other Fraud Act CI 862 Black Lung (923) CI 490 Cable/Sat TV
ID 160 Stockholders' Suits 0 355 Motor Vehicle CI 371 Truth in Lending 0 720 Labor/Management 0 863 DIWC/DIWW (405(g)) CI 850 Securities/Commodities/
CI 190 Other Contract Product Liability 0 380 Other Personal Relations CI 864 SSID Title XVI ExchangeO 195 Contract Product Liability CI 360 Other Personal Property Damage CI 740 Railway Labor Act 0 865 RSI (405(g)) 0 890 Other Statutory Actions
CI 196 Franchise Injury 0 385 Property Damage CI 751 Family and Medical 0 891 Agricultural Acts
Medical Malpractice 0 790 Other Labor Litigation 0 895 Freedom ofInformation
REAL PROPER n CIVIL mows PRISONER PE1ITIONS ID 791 Employee Retirement FEDERAL TAX SUITS Act
CI 210 Land Condemnation 0 440 Other Civil Rights Habeas Corpus: Income Security Act CI 870 Taxes (U.S. Plaintiff ID 896 Arbitration
0 220 Foreclosure CI 441 Voting 0 463 Alien Detainee or Defendant) CI 899 Administrative Procedure
CI 230 Rent Lease & Ejectment 0 442 Employment CI 510 Motions to Vacate 0 871 IRS—Third Party Act/Review or Appeal of
CI 240 Torts to Land 0 443 Housing/ Sentence 26 USC 7609 Agency Decision
0 245 Tort Product Liability Accommodations 0 530 General CI 950 Constitutionality of
CI 290 All Other Real Property 0 445 Amer. w/Disabilities CI 535 Death Penalty IMKIGRATION State Statutes
Employment Other: 0 462 Naturalization ApplicationCI 446 Amer. w/Disabilities 0 540 Mandamus & Other 0 465 Other Immigration
Other 0 550 Civil Rights Actions
0 448 Education CI 555 Prison ConditionCI 560 Civil Detainee
Conditions ofConfinement
V. ORIGIN (Place an 'X" in One Box Only)X1 Original 0 2 Removed from 0 3 Remanded from 0 4 Reinstated or 0 5 Transferred from ID 6 Multidistrict 0 8 Multidistrict
Proceeding State Court Appellate Court Reopened Another District Litigation Litigation(specifr) Transfer Direct File
Cite the U.S. Civil Statute under which you are filing (Do not citejurisdictional statutes unless diversity):28 U.S.C. 1332 (a)(1)
VI. CAUSE OF ACTION Brief description of cause:
Products liability litigationVII. REQUESTED IN 0 clikK IF rims Is A CLASS ACTION DEMAND CHECK YES only ifdemanded in complaint:
COMPLAINT: UNDER RULE 23, F.R.Cv.P. JURY DEMAND: X Yes 0 No
VIII. RELATED CASE(S)IF ANY (See instructions):
JUDGE DOCKET NUMBER
DATE SIGNATURE OF ATTORNEY OF RECORD
02/08/2017 Is/ ROGER C. DENTONFOR OFFICE USE ONLY
RECEIPT 6 AMOUNT APPLYING1FP JUDGE MAG. JUDGE
AO 440 (Rev. 06/12) Summons in a Civil Action
United States District Courtfor the
Southern District of Illinois
)IRMA COLEMAN and JAMES B. COLEMAN
))))Plaintiff(s)
) Civil Action No. 3:17-cv-130v.
)ASTRAZENECA PHARMACEUTICALS LP.
ASTRAZENECA LP, THE PROCTER & GAMBLE )
MANUFACTURING COMPANY and THE PROCTOR )
& GAMBLE COMPANY
)
))Defendant(s)
SUMMONS IN A CIVIL ACTION
To: (Defendant's name and address)Astrazeneca LP
c/o Corporation Trust
1209 Orange Street
Wilmington, DE 19806
A lawsuit has been filed against you.
Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you
are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ.P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 ofthe Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff s attorney,whose name and address are:
Roger C. Denton
Schlichter, Bogard & Denton, LLP
100 South 4th Street, Suite 1200
St. Louis, MO 63102
If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint.
You also must file your answer or motion with the court.
CLERK OF COURT
Date:Signature ofClerk or Deputy Clerk
Case 3:17-cv-00130 Document 1-2 Filed 02/08/17 Page 1 of 4 Page ID #33
AO 440 (Rev. 06/12) Summons in a Civil Action
United States District Courtfor the
Southern District of Illinois
)IRMA COLEMAN and JAMES B. COLEMAN
))))Plaintiff(s)
) Civil Action No. 3:17-cv-130v.)
ASTRAZENECA PHARMACEUTICALS LP,
ASTRAZENECA LP, THE PROCTER & GAMBLE )
MANUFACTURING COMPANY and THE PROCTOR )
& GAMBLE COMPANY
)
))Defendant(s)
SUMMONS IN A CIVIL ACTION
To: (Defendant's name and address)Astrazeneca Pharmaceuticals LP
c/o Corporation Trust
1209 Orange Street
Wilmington, DE 19806
A lawsuit has been filed against you.
Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you
are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ.
P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of
the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff s attorney,
whose name and address are:Roger C. Denton
Schlichter, Bogard & Denton, LLP
100 South 4th Street, Suite 1200
St. Louis, MO 63102
If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint.
You also must file your answer or motion with the court.
CLERK OF COURT
Date:Signature ofClerk or Deputy Clerk
Case 3:17-cv-00130 Document 1-2 Filed 02/08/17 Page 2 of 4 Page ID #34
AO 440 (Rev. 06/12) Summons in a Civil Action
United States District Courtfor the
Southern District of Illinois
)IRMA COLEMAN and JAMES B. COLEMAN
))))Plaintiff(s)
) Civil Action No. 3:17-cv-130v.
)ASTRAZENECA PHARMACEUTICALS LP,
ASTRAZENECA LP, THE PROCTER & GAMBLE )
MANUFACTURING COMPANY and THE PROCTOR )
& GAMBLE COMPANY
)
))Defendant(s)
SUMMONS IN A CIVIL ACTION
To: (Defendant's name and address)The Proctor & Gamble Manufacturing Company
1 Proctor & gamble Plaza
Cincinnati, OH 45202
A lawsuit has been filed against you.
or 60 days if youWithin 2 1 days after service of this summons on you (not counting the day you received it)are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ.P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 ofthe Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff s attorney,whose name and address are:
Roger C. Denton
Schlichter, Bogard & Denton, LLP
100 South 4th Street, Suite 1200
St. Louis, MO 63102
If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint.You also must file your answer or motion with the court.
CLERK OF COURT
Date:Signature ofClerk or Deputy Clerk
Case 3:17-cv-00130 Document 1-2 Filed 02/08/17 Page 3 of 4 Page ID #35
AO 440 (Rev. 06/12) Summons in a Civil Action
United States District Courtfor the
Southern District of Illinois
IRMA COLEMAN and JAMES B. COLEMAN )))))Plaintiff(s)
' Civil Action No. 3:17-cv-130v.
)ASTRAZENECA PHARMACEUTICALS LP,
ASTRAZENECA LP, THE PROCTER & GAMBLE )
MANUFACTURING COMPANY and THE PROCTOR )
& GAMBLE COMPANY
)
))Defendant(s)
SUMMONS IN A CIVIL ACTION
To: (Defendant's name and address)The Proctor & Gamble Company
1 Proctor & gamble Plaza
Cincinnati, OH 45202
A lawsuit has been filed against you.
Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you
are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ.
P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of
the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff s attorney,whose name and address are:
Roger C. Denton
Schlichter, Bogard & Denton, LLP
100 South 4th Street, Suite 1200
St. Louis, MO 63102
If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint.
You also must file your answer or motion with the court.
CLERK OF COURT
Date:Signature ofClerk or Deputy Clerk
Case 3:17-cv-00130 Document 1-2 Filed 02/08/17 Page 4 of 4 Page ID #36